Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.01 USD
0.00 (9.09%)
Updated Sep 18, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Sorrento Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 63 | 53 | 40 | 31 |
Cost Of Goods | NA | 33 | 13 | 10 | 12 |
Gross Profit | NA | 29 | 40 | 30 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 534 | 441 | 275 | 279 |
Income After Depreciation & Amortization | 0 | -504 | -401 | -245 | -259 |
Non-Operating Income | NA | -49 | -51 | -46 | -64 |
Interest Expense | NA | 9 | 10 | 20 | 36 |
Pretax Income | NA | -562 | -463 | -311 | -360 |
Income Taxes | NA | -2 | -34 | -2 | 0 |
Minority Interest | NA | -5 | -1 | -16 | -71 |
Investment Gains/Losses | NA | -18 | 0 | -6 | -4 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -578 | -429 | -314 | -363 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -573 | -428 | -298 | -292 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -484 | -389 | -234 | -248 |
Depreciation & Amortization (Cash Flow) | NA | 20 | 12 | 11 | 11 |
Income After Depreciation & Amortization | 0 | -504 | -401 | -245 | -259 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 229.82 | 140.51 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -1.30 | -2.12 |
Diluted Net EPS (GAAP) | NA | -1.37 | -1.45 | -1.30 | -2.35 |
Fiscal Year end for Sorrento Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 15.03 |
Cost Of Goods | NA | NA | NA | NA | 8.45 |
Gross Profit | NA | NA | NA | NA | 6.57 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 83.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -77.24 |
Non-Operating Income | NA | NA | NA | NA | -27.96 |
Interest Expense | NA | NA | NA | NA | 2.67 |
Pretax Income | NA | NA | NA | NA | -107.87 |
Income Taxes | NA | NA | NA | NA | 0.67 |
Minority Interest | NA | NA | NA | NA | -13.32 |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | -108.54 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -95.21 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 551.28 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.17 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -0.17 |